Olanzapine increases weight and serum triglyceride levels

Journal of Clinical Psychiatry

Volumn 60, Issue 11, 1999, Pages 767-770

  Osser, David N ^a   Najarian, Dean M ^a   Dufresne, Robert L ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GEMFIBROZIL; LITHIUM; OLANZAPINE; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VALPROATE SEMISODIUM;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG UTILIZATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 0032724490     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n1109     Document Type: Article

References (24)

1. Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979;40:528-530
2. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(9, suppl B):157-160
3. Allison DB, Mentor JL, Heo M, et al. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Ontario, Canada. Abstract NR497:202
4. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
5. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
6. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-2081
7. Spivak B, Mester R, Gonen N, et al. Clozapine treatment, suicidality, aggressiveness, serum lipids and monoamine plasma levels. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 4, 1998; Toronto, Ontario, Canada. Abstract NR717:262
8. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81(4A):18B-25B
9. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57(suppl 11):4-11
10. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72
11. Stahl SM. Neuropharmacology of obesity: my receptors made me eat it [BRAINSTORMS]. J Clin Psychiatry 1998;59:447-448
12. Gudlesky GA, Nash JF, Koenig JI, et al. Neuroendocrine effects of typical and atypical antipsychotics in the rat. Psychopharmacol Bull 1987;23: 482-486
13. Coddington RD, Bruch H. Gastric perceptivity in normal, obese, and schizophrenic subjects. Psychosomatics 1970;9:571-579
14. Lawson WB, Karson CN. Clinical correlates of body weight changes in schizophrenia. J Neuropsychiatry Clin Neurosci 1994;6:187-188
15. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-440
16. Zyprexa (olanzapine). Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics; 1998:1512-1516
17. Clozaril (clozapine). Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics; 1998:1834-1838
18. Seroquel (quetiapine). Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics; 1999:3428-3432
19. Ghaeli P, Dufresne RL. Elevated serum triglycerides on clozapine resolve with risperidone [abstract]. Pharmacotherapy 1995;15:382
20. Sasaki J, Kumagae G, Sata T, et al. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis 1984;51(2-3):163-169
21. Sporn J, Goldstein L, Sachs GS. New-onset diabetes associated with starting olanzapine in patients with schizoaffective and bipolar disorders. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 4, 1998; Toronto, Ontario, Canada. Abstract NR673:250
22. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111
23. Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299
24. Diebold K, Michel G, Schweizer J, et al. Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders? Pharmacopsychiatry 1998;31:60-67